Literature DB >> 33494243

Surgical Advances in Osteosarcoma.

Marcus J Brookes1, Corey D Chan1, Bence Baljer1, Sachin Wimalagunaratna1, Timothy P Crowley2,3, Maniram Ragbir2,3, Alistair Irwin2, Zakareya Gamie1, Thomas Beckingsale2, Kanishka M Ghosh2, Kenneth S Rankin1,2.   

Abstract

Osteosarcoma (OS) is the most common primary bone cancer in children and, unfortunately, is associated with poor survival rates. OS most commonly arises around the knee joint, and was traditionally treated with amputation until surgeons began to favour limb-preserving surgery in the 1990s. Whilst improving functional outcomes, this was not without problems, such as implant failure and limb length discrepancies. OS can also arise in areas such as the pelvis, spine, head, and neck, which creates additional technical difficulty given the anatomical complexity of the areas. We reviewed the literature and summarised the recent advances in OS surgery. Improvements have been made in many areas; developments in pre-operative imaging technology have allowed improved planning, whilst the ongoing development of intraoperative imaging techniques, such as fluorescent dyes, offer the possibility of improved surgical margins. Technological developments, such as computer navigation, patient specific instruments, and improved implant design similarly provide the opportunity to improve patient outcomes. Going forward, there are a number of promising avenues currently being pursued, such as targeted fluorescent dyes, robotics, and augmented reality, which bring the prospect of improving these outcomes further.

Entities:  

Keywords:  osteosarcoma; sarcoma; surgery

Year:  2021        PMID: 33494243     DOI: 10.3390/cancers13030388

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Intercalary and geographic lower limb tumor resections with the use of 3D printed Patient Specific Instruments- when less is more.

Authors:  Amit Benady; J Sam Meyer; Yuval Ran; Yaron Mor; Ron Gurel; Netta Rumack; Eran Golden; Yair Gortzak; Ortal Segal; Omri Merose; Amir Sternheim; Solomon Dadia
Journal:  J Orthop       Date:  2022-05-06

2.  LncRNA KASRT Serves as a Potential Treatment Target by Regulating SRSF1-Related KLF6 Alternative Splicing and the P21/CCND1 Pathway in Osteosarcoma: An In Vitro and In Vivo Study.

Authors:  Kai Chen; Cheng Li; Shuai Huang; Yu Chen; Xiaodong Zhu
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

3.  Bavachin Induces Ferroptosis through the STAT3/P53/SLC7A11 Axis in Osteosarcoma Cells.

Authors:  Yi Luo; Xu Gao; Luetao Zou; Miao Lei; Junming Feng; Zhenming Hu
Journal:  Oxid Med Cell Longev       Date:  2021-10-18       Impact factor: 6.543

4.  Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA.

Authors:  Junyi Wang; Lichan Yuan; Xiaohong Xu; Zhongyin Zhang; Yuhuan Ma; Leilei Hong; Junqing Ma
Journal:  Cell Death Dis       Date:  2021-12-11       Impact factor: 8.469

5.  Spinal giant cell-rich osteosarcoma-diagnostic dilemma and treatment strategy: A case report.

Authors:  Chen-Sheng Tseng; Chia-En Wong; Chi-Chen Huang; Hao-Hsiang Hsu; Jung-Shun Lee; Po-Hsuan Lee
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

6.  Risk stratification system and web-based nomogram constructed for predicting the overall survival of primary osteosarcoma patients after surgical resection.

Authors:  Bing Gao; Meng-Die Wang; Yanan Li; Fei Huang
Journal:  Front Public Health       Date:  2022-08-05

Review 7.  Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.

Authors:  Xiaozhuo Gao; Bo Gao; Shenglong Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.